Replimune (REPL) Amortization of Deferred Charges (2019 - 2025)
Replimune's (REPL) quarterly Amortization of Deferred Charges came in at $425000.0 in Q4 2025, up 8.42% year-on-year from $392000.0 in Q4 2024, and up 2.66% quarter-over-quarter from $414000.0 in Q3 2025.
Replimune (REPL) Amortization of Deferred Charges (2019 - 2025) Analysis & Trends
Replimune has disclosed Amortization of Deferred Charges across 5 years of filings, most recently posting $425000.0 for Q4 2025.
- Amortization of Deferred Charges for Q4 2025 came in at $425000.0, up 8.42% year-over-year; the trailing twelve-month figure through Dec 2025 was $1.7 million (up 9.64% YoY), and the FY2025 annual result was $1.6 million, up 35.06% from the prior year.
- Amortization of Deferred Charges came in at $425000.0 for Q4 2025 at Replimune, up from $414000.0 in the prior quarter.
- In the past five years, Amortization of Deferred Charges ranged from a high of $425000.0 in Q4 2025 to a low of $256000.0 in Q3 2023.
- The 3-year median for Amortization of Deferred Charges is $383000.0 (2024), against an average of $362090.9.
- Across the five-year window, Amortization of Deferred Charges surged 49.03% in 2024 and gained 8.36% in 2025, its largest moves.
- Replimune's Amortization of Deferred Charges stood at $273000.0 in 2023, then soared by 43.59% to $392000.0 in 2024, then gained by 8.42% to $425000.0 in 2025.
- The last three Amortization of Deferred Charges figures came in at $425000.0 (Q4 2025), $414000.0 (Q3 2025), and $415000.0 (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - |
| 10 | Replimune | 780.01 Mn | 510.88 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 425,000.00 |
| Dec 31, 2025 | 425,000.00 |
| Sep 30, 2025 | 414,000.00 |
| Sep 30, 2025 | 414,000.00 |
| Jun 30, 2025 | 415,000.00 |
| Jun 30, 2025 | 415,000.00 |
| Mar 31, 2025 | 418,000.00 |
| Mar 31, 2025 | 418,000.00 |
| Dec 31, 2024 | 392,000.00 |
| Dec 31, 2024 | 392,000.00 |
| Sep 30, 2024 | 375,000.00 |
| Sep 30, 2024 | 375,000.00 |
| Jun 30, 2024 | 383,000.00 |
| Jun 30, 2024 | 383,000.00 |
| Mar 31, 2024 | 375,000.00 |
| Mar 31, 2024 | 375,000.00 |
| Dec 31, 2023 | 273,000.00 |
| Dec 31, 2023 | 273,000.00 |
| Sep 30, 2023 | 256,000.00 |
| Sep 30, 2023 | 256,000.00 |